Skip to main content
. Author manuscript; available in PMC: 2010 Dec 1.
Published in final edited form as: Cancer Res. 2009 Nov 17;69(23):8941–8948. doi: 10.1158/0008-5472.CAN-09-1828

Figure. 2.

Figure. 2

Therapeutic efficacy of 225Ac-, 213Bi- and 90Y-7.16.4. A, Kaplan-Meier survival curves of neu-N transgenic mice treated 3 days after i.v. injection of 1×105 NT2.5 cells. Neu-N mice were treated with 400 nCi 225Ac-7.16.4 (open triangle, n=12), 120 μCi 213Bi-7.16.4 (closed circle, n=10), 120 μCi 90Y-7.16.4 (open square, n=5) or untreated (closed diamond, n=10). B, Neu-N mice were treated 3 days after tumor cell inoculation with 100 μg unlabeled 7.16.4 (open diamond, n=5), 400 nCi 225Ac-Rituximab (open triangle, n=5), 200 nCi 225Ac-7.16.4 (open square, n=5), 200 nCi + 200 nCi 225Ac-7.16.4 (closed triangle, n=5) or untreated (open circle, n=4) C, neu-N mice were treated 18 days after tumor cell inoculation with 400 nCi 225Ac-7.16.4 (open triangle, n=5), 120 μCi 213Bi-7.16.4 (closed circle, n=5), 120 μCi 90Y-7.16.4 (open square, n=5) or untreated (closed diamond, n=10).